Imatinib in Gastrointestinal Stromal Tumor: Does Treatment Duration Matter?

Publisher： Karger

E-ISSN： 1423-0232|77|3-4|157-161

ISSN： 0030-2414

Source： Oncology, Vol.77, Iss.3-4, 2009-09, pp. : 157-161

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Critical Update and Emerging Trends in Imatinib Treatment for Gastrointestinal Stromal Tumor

By  

Reviews on Recent Clinical Trials, Vol. 2, Iss. 1, 2007-01 ,pp. : 43-48

Bentham Science Publishers

Access to resources Recommend Favorite

Ten Years of Treatment with 400 mg Imatinib per Day in a Case of Advanced Gastrointestinal Stromal Tumor

By  

Case Reports in Oncology, Vol. 4, Iss. 3, 2011-10 ,pp. : 505-511

Karger

Access to resources Recommend Favorite

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours

By  

Case Reports in Oncology, Vol. 4, Iss. 1, 2011-04 ,pp. : 204-210

Karger

Access to resources Recommend Favorite

Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib

By  

CANCER, Vol. 120, Iss. 15, 2014-08 ,pp. : 2325-2333

John Wiley & Sons Inc

Access to resources Recommend Favorite

Imatinib Mesylate Treatment for Advanced Gastrointestinal Stromal Tumor: A Pilot Study Focusing on Patients Experiencing Sole Liver Metastasis after a Prior Radical Resection

By  

Oncology, Vol. 73, Iss. 5-6, 2008-05 ,pp. : 324-327

Karger

Access to resources Recommend Favorite